Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
| Location: | District of Columbia |
|---|---|
| Posted: | Oct 1, 2025 |
| Due: | Oct 2, 2025 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | ARPA-H-SN-25-131 |
| Publication URL: | To access bid details, please log in. |
- Contract Opportunity Type: Special Notice (Updated)
- Updated Published Date: Oct 01, 2025 05:11 pm EDT
- Original Published Date: Sep 25, 2025 09:02 am EDT
- Updated Response Date: Oct 02, 2025 08:59 am EDT
- Original Response Date: Sep 30, 2025 11:59 pm EDT
- Inactive Policy: 15 days after response date
- Updated Inactive Date: Oct 17, 2025
- Original Inactive Date: Oct 15, 2025
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
-
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
-
Place of Performance:
Washington , DC 20005USA
The purpose of this amendment is to:
1. Extend the registration deadline for lightning talks and sidebars to October 2, 2025 at 08:59AM ET.
2. Extend the available days/hours for lightning talks and sidebars. Lightning talks and sidebars slots will now be available on October 3. 2025. Slots for the October 3rd lightning talks and sidebars will be available between 11:00AM ET to 2:00PM ET. In addition, slots for the October 2nd sidebars will now be available between 11:00AM ET and 7:00PM ET.
Please see the revised Special Notice document for additional details.
------------------------------------------------------------------------------------------------------------
This Special Notice (SN) is intended to alert the scientific community to a newly approved ARPA-H Program and notify potential proposers of an associated Proposers’ Day (PD). Under the cognizance of HSF, ARPA-H is publishing an Innovative Solutions Opening (ISO) for the Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program no later than September 25, 2025, please monitor SAM.gov for updates (ARPA-H-SOL-25-122).
For additional PD details and registration information see the attached special notice (ARPA-H-SN-25-131).
For more information about the THRIVE program visit: https://arpa-h.gov/explore-funding/programs/thrive
- 1301 K Street NW Suite 1200 West
- Washington , DC 20005
- USA
- THRIVE Program
- THRIVE@arpa-h.gov
- Oct 01, 2025 05:11 pm EDTSpecial Notice (Updated)
- Sep 25, 2025 09:02 am EDT Special Notice (Original)
Related Document
| Sep 25, 2025 | [Special Notice (Original)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |
With GovernmentContracts, you can:
- Find more opportunities and win more business
- Receive daily alerts for all new bid opportunities
- Get contract opportunities matched to your business
See also
Follow Environmental Chamber Active Contract Opportunity Notice ID 2031ZA26Q00098 Related Notice Department/Ind. Agency
TREASURY, DEPARTMENT OF THE
Bid Due: 6/18/2026
Follow STAA Infant Formula Testing (108969) Active Contract Opportunity Notice ID 05GA0A26Q0048 Related
GOVERNMENT ACCOUNTABILITY OFFICE
Bid Due: 6/17/2026
Follow DOC Architect and Engineering IDIQ Active Contract Opportunity Notice ID AA-FEQ-WC-O-26-00495 Related
COMMERCE, DEPARTMENT OF
Bid Due: 6/16/2026
Follow Request for Information: Commercial Off-the-Shelf (COTS) Electronic Records Management (ERM) System Active
ENERGY, DEPARTMENT OF
Bid Due: 6/17/2026